{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:26:26Z","timestamp":1790619986068,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1470,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1600-0609.2011.01680.x","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T22:07:27Z","timestamp":1310508447000},"page":"426-433","source":"Crossref","is-referenced-by-count":21,"title":["Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia"],"prefix":"10.1111","volume":"87","author":[{"given":"Kai Uwe","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Zin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"von Neuhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Wunderle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joerg","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,23]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic featurespreict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia. Justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.leu.2402537","article-title":"Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course","volume":"16","author":"Stilgenbauer","year":"2002","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.leukres.2009.07.008","article-title":"Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70\u2003years","volume":"34","author":"Faderl","year":"2010","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008312432416","article-title":"Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study","volume":"10","author":"Rummel","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB10|cit10","first-page":"2123","article-title":"Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia - final results of a German randomized phase-III study","volume":"106","author":"Rummel","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB11|cit11","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-Sponsored Working Group Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1200\/JCO.2009.22.0442","article-title":"Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly Active chemoimmunotherapy regimen for chronic lymphocytic leukemia","volume":"27","author":"Bosch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","article-title":"Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses","volume":"27","author":"Lamanna","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.exphem.2010.09.001","article-title":"Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicine or epirubicin","volume":"38","author":"Skribek","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB22|cit22","first-page":"278","article-title":"Preliminary results of the UK MRC CLL trial in chronic lymphocytic leukaemia-CLL 3. Abstract 0 - 114 in: Proceedings of the 27th Congress of the International Society of Haematology (ISH-EHA)","volume":"102","author":"Catovsky","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","author":"CLL Trialists\u2019 Collaborative Group","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1600-0609.2011.01680.x-BIB24|cit24","first-page":"781","article-title":"Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial","volume":"112","author":"Stilgenbauer","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01680.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01680.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:10:59Z","timestamp":1625638259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01680.x"}},"subtitle":["FER in CLL and PLL"],"short-title":[],"issued":{"date-parts":[[2011,8,23]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01680.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,23]]}}}